LEO 159074

LEO 159074 is the principal metabolite (specifically, the N-glucuronide metabolite) of the investigational drug LEO 153339, which is under development by LEO Pharma for dermatological indications such as psoriasis. LEO 159074 is generated in vivo following the administration of LEO 153339. Its pharmacokinetics are studied to assess the metabolism and elimination of the parent compound. LEO 153339 reportedly has a similar mode of action to secukinumab, which is an interleukin-17A (IL-17A) inhibitor, suggesting the parent compound (and by extension, its metabolite) likely targets the IL-17A pathway, central to the inflammatory processes in diseases like psoriasis[3][5].